GlycoMimetics (NASDAQ:GLYC – Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect GlycoMimetics to post earnings of ($0.15) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last posted its quarterly earnings results on Wednesday, March 27th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. The company had revenue of $0.01 million during the quarter. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
GlycoMimetics Stock Down 10.0 %
NASDAQ:GLYC opened at $1.62 on Thursday. GlycoMimetics has a twelve month low of $1.11 and a twelve month high of $3.53. The firm has a market capitalization of $104.41 million, a price-to-earnings ratio of -2.79 and a beta of 2.18. The stock’s 50 day moving average price is $2.58 and its two-hundred day moving average price is $2.33.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on GLYC
About GlycoMimetics
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- Consumer Discretionary Stocks Explained
- AMD is Down 35%. Now is the Time to Buy the Dip
- Investing in the High PE Growth Stocks
- Amazon Stands Tall: New Highs Are in Sight
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.